GO:0006640 monoacylglycerol biosynthetic process: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006640 monoacylglycerol biosynthetic process describes the enzymatic formation of monoacylglycerol, a glycerol ester with a single fatty acyl chain.
• Monoacylglycerol is a central intermediate in glycerolipid metabolism and a precursor for more complex lipids such as bis(monoacylglycero)phosphate (BMP).
• The pathway is linked to lysosomal lipid degradation, membrane remodeling, and neurodegenerative disease mechanisms.
• Key enzymes include phospholipases (e.g., PLA2G15, PLD3, PLD4) and acyltransferases that generate or consume monoacylglycerol.
• Dysregulation of monoacylglycerol metabolism is implicated in lysosomal storage disorders, Parkinson's disease, and metabolic conditions.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect gene function in this pathway.
Description
Monoacylglycerol biosynthetic process (GO:0006640) is defined as the chemical reactions and pathways resulting in the formation of monoacylglycerol, any ester of glycerol in which one hydroxyl group is acylated with a fatty acid and the others remain non-esterified. This process is fundamental to lipid metabolism because monoacylglycerol serves as a key intermediate in the synthesis of diacylglycerol, triacylglycerol, and phospholipids, and it also acts as a signaling molecule. In recent years, monoacylglycerol has gained attention as a precursor for bis(monoacylglycero)phosphate (BMP), a phospholipid critical for lysosomal function and lipid degradation. Understanding how monoacylglycerol is synthesized and regulated is therefore essential for researchers studying lysosomal biology, neurodegeneration, and metabolic disorders. This article integrates authoritative QuickGO data with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental models relevant to GO:0006640.
monoacylglycerol biosynthetic process At A Glance
| GO ID | GO:0006640 |
|---|---|
| GO term | monoacylglycerol biosynthetic process |
| Ontology | biological_process |
| Synonym | monoacylglycerol anabolism, monoacylglycerol biosynthesis, monoacylglycerol formation, monoacylglycerol synthesis, monoglyceride biosynthesis, monoglyceride biosynthetic process |
| Major function | Synthesis of monoacylglycerol, a key intermediate in glycerolipid metabolism and precursor for BMP |
| Related pathways | Glycerolipid metabolism, lysosomal lipid degradation, phospholipid remodeling |
| Key enzymes | PLA2G15, PLD3, PLD4, and acyltransferases |
| Disease relevance | Lysosomal storage disorders, Parkinson's disease, metabolic disorders |
What Is GO:0006640?
The monoacylglycerol biosynthetic process (GO:0006640) encompasses the enzymatic steps that produce monoacylglycerol, a glycerol molecule esterified with exactly one fatty acid. This definition is based on the QuickGO entry, which specifies that monoacylglycerol is any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified. The process includes both de novo synthesis and the generation of monoacylglycerol from larger lipids via hydrolysis, as seen in lysosomal BMP catabolism.
Why Is monoacylglycerol biosynthetic process Important in Cell Biology?
The monoacylglycerol biosynthetic process is important because monoacylglycerol is not only a metabolic intermediate but also a precursor for bis(monoacylglycero)phosphate (BMP), a phospholipid that is essential for lysosomal lipid degradation and membrane integrity. Disruptions in this pathway have been linked to lysosomal dysfunction, neurodegeneration, and metabolic diseases. Moreover, monoacylglycerol and its derivatives are emerging as biomarkers and therapeutic targets in conditions such as Parkinson's disease and Niemann-Pick type C.
• Provides monoacylglycerol for synthesis of diacylglycerol and triacylglycerol, central to energy storage.
• Serves as a precursor for bis(monoacylglycero)phosphate (BMP), critical for lysosomal function.
• Dysregulation is linked to lysosomal storage disorders and neurodegeneration.
• Enzymes like PLA2G15 and PLD3/4 are potential therapeutic targets.
• Monoacylglycerol metabolism affects membrane remodeling and lipid signaling.
• Relevant to metabolic diseases such as obesity and fatty liver.
• Plays a role in cold exposure adaptation via hepatic lipid remodeling.
• Involved in cholesterol trafficking and NPC1 deficiency.
• Biomarker potential in neurodegenerative diseases.
• CRISPR models enable functional dissection of pathway genes.
What Happens During monoacylglycerol biosynthetic process?
Substrate availability and precursor lipids
In simple terms: The process starts with lipids that can be broken down or modified to release monoacylglycerol.
Monoacylglycerol biosynthesis can occur through the hydrolysis of larger lipids such as phosphatidylglycerol or BMP. For example, phospholipase A2 group XV (PLA2G15) hydrolyzes BMP to produce monoacylglycerol, a key step in lysosomal lipid catabolism. Similarly, PLD3 and PLD4 synthesize S,S-BMP, which can be further processed to monoacylglycerol. These reactions require the availability of precursor phospholipids and appropriate enzymes in specific cellular compartments.
Enzymatic hydrolysis and acyl chain removal
In simple terms: Enzymes cut off fatty acid chains from larger lipids to create monoacylglycerol.
The core enzymatic step involves phospholipases and hydrolases that remove acyl chains from diacylglycerol or phospholipids. PLA2G15 acts as a BMP hydrolase, generating monoacylglycerol from BMP. Other enzymes, such as those in the PLD family, contribute to BMP synthesis and subsequent monoacylglycerol formation. This hydrolysis is tightly regulated and occurs in lysosomes and other organelles.
Intra- and extralysosomal pathways
In simple terms: Monoacylglycerol can be made inside lysosomes or in other parts of the cell.
Studies have shown functionally overlapping intra- and extralysosomal pathways for BMP synthesis, which is closely linked to monoacylglycerol production. This compartmentalization ensures that monoacylglycerol is available for different cellular needs, including membrane remodeling and lipid signaling. The balance between these pathways is critical for lysosomal health.
Regulation by kinase activity and disease-linked proteins
In simple terms: Certain proteins, like LRRK2, can control how much monoacylglycerol is made.
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, including BMP and monoacylglycerol metabolism. This suggests that monoacylglycerol biosynthesis is subject to regulation by signaling kinases and may be disrupted in neurodegenerative conditions. Understanding these regulatory mechanisms is essential for therapeutic development.
Key Genes Involved in GO:0006640 monoacylglycerol biosynthetic process
The following genes and proteins are experimentally implicated in monoacylglycerol biosynthetic process and related lipid pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G15 | BMP hydrolase generating monoacylglycerol | Lysosomal disease target |
| PLD3 | Synthesizes S,S-BMP, precursor to monoacylglycerol | Lysosomal lipid degradation |
| PLD4 | Synthesizes S,S-BMP, precursor to monoacylglycerol | Lysosomal lipid degradation |
| LRRK2 | Regulates lysosomal lipids including BMP | Parkinson's disease |
| NPC1 | Cholesterol trafficking, linked to BMP metabolism | Niemann-Pick type C |
| ABHD6 | Monoacylglycerol lipase (implied by pathway) | Endocannabinoid signaling |
| MGLL | Monoacylglycerol lipase | Lipid metabolism |
| DGAT1 | Diacylglycerol acyltransferase, uses monoacylglycerol | Triglyceride synthesis |
| DGAT2 | Diacylglycerol acyltransferase | Triglyceride synthesis |
| MOGAT1 | Monoacylglycerol O-acyltransferase | Glycerolipid synthesis |
| MOGAT2 | Monoacylglycerol O-acyltransferase | Glycerolipid synthesis |
| MOGAT3 | Monoacylglycerol O-acyltransferase | Glycerolipid synthesis |
| LPL | Lipoprotein lipase, produces monoacylglycerol | Lipid metabolism |
| PNPLA2 | Adipose triglyceride lipase | Lipolysis |
| CES1 | Carboxylesterase 1 | Lipid metabolism |
| CES2 | Carboxylesterase 2 | Lipid metabolism |
| GDE1 | Glycerophosphodiester phosphodiesterase | Monoacylglycerol production |
How Is monoacylglycerol biosynthetic process Regulated?
Monoacylglycerol biosynthesis is regulated at multiple levels, including enzyme expression, subcellular localization, and post-translational modifications. LRRK2 kinase activity has been shown to regulate Parkinson's disease-relevant lipids at the lysosome, including BMP and monoacylglycerol metabolism. Additionally, cold exposure induces hepatic lipid remodeling that directly regulates BMP lipids by phospholipase A2 group XV, affecting monoacylglycerol production. These findings indicate that both environmental cues and disease-associated kinases can modulate this pathway.
monoacylglycerol biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LRRK2 | Parkinson's disease | Knock-in of G2019S mutation in iPSCs |
| PLA2G15 | Lysosomal disease | Knockout in HeLa or fibroblasts |
| PLD3 | Lysosomal lipid degradation | Knockout in HEK293T |
| PLD4 | Lysosomal lipid degradation | Knockout in HEK293T |
| NPC1 | Niemann-Pick type C | Knockout in CHO or patient fibroblasts |
Neurodegenerative diseases
Monoacylglycerol metabolism is linked to neurodegenerative diseases such as Parkinson's disease. LRRK2 kinase activity regulates lysosomal lipids including BMP, and mutations in LRRK2 are a common cause of familial Parkinson's disease. Lipids are emerging as biomarkers in neurodegenerative diseases, with monoacylglycerol and related species showing potential.
Lysosomal storage disorders
Defects in monoacylglycerol biosynthesis and BMP metabolism contribute to lysosomal storage disorders. PLA2G15 is a BMP hydrolase, and its targeting ameliorates lysosomal disease in preclinical models. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes, and their dysfunction leads to lipid accumulation.
Metabolic and cholesterol disorders
Monoacylglycerol metabolism intersects with cholesterol trafficking. In NPC1 deficiency, phospholipid treatment reduces intracellular cholesterol accumulation, and BMP/monoacylglycerol pathways are implicated. Hepatic lipid remodeling in cold exposure reveals direct regulation of BMP lipids by PLA2G15, linking monoacylglycerol to systemic metabolic adaptation.
From monoacylglycerol biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G15 affect monoacylglycerol levels? | PLA2G15 knockout cell line |
| Does LRRK2 kinase activity regulate BMP/monoacylglycerol? | LRRK2 knock-in or knockout neurons |
| Can PLD3/PLD4 rescue BMP synthesis? | PLD3/PLD4 overexpression |
| What is the role of extralysosomal BMP synthesis? | Knockout of intra- vs extralysosomal enzymes |
| Does cold exposure alter hepatic monoacylglycerol? | Mouse models with PLA2G15 knockout |
| Can phospholipid treatment reduce cholesterol in NPC1? | NPC1 knockout cells treated with phospholipids |
How to Study the monoacylglycerol biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS) | Monoacylglycerol and BMP species | Quantify pathway flux |
| CRISPR knockout screen | Gene essentiality for monoacylglycerol production | Identify novel regulators |
| Immunofluorescence | Subcellular localization of enzymes | Determine organelle site |
| Enzymatic assay | Hydrolase/acyltransferase activity | Validate enzyme function |
| RNA-seq | Transcriptional changes in pathway genes | Assess regulation |
| Western blot | Protein expression levels | Confirm knockout/overexpression |
| Co-immunoprecipitation | Protein-protein interactions | Identify complexes |
| Live-cell imaging | Dynamic lipid changes | Monitor lysosomal function |
Lipidomics and mass spectrometry
Lipidomics using mass spectrometry is the primary method to quantify monoacylglycerol and related lipids such as BMP. Studies have used this approach to measure changes in response to enzyme knockout or cold exposure. It allows precise identification of lipid species and their acyl chain composition.
CRISPR-based genetic screens
CRISPR knockout screens can identify genes required for monoacylglycerol biosynthesis. For example, genome-wide screens have uncovered roles for PLD3 and PLD4 in BMP synthesis. These screens are powerful for discovering novel regulators of the pathway.
Fluorescence microscopy and imaging
Imaging techniques, including immunofluorescence and live-cell imaging, are used to localize enzymes like PLA2G15 and monitor lysosomal lipid accumulation. This helps determine subcellular sites of monoacylglycerol production.
Enzymatic activity assays
In vitro enzymatic assays with recombinant proteins or cell lysates measure hydrolase or acyltransferase activity specific to monoacylglycerol synthesis. These assays are essential to confirm direct roles of candidate enzymes.
How CRISPR Can Be Used to Study GO:0006640 monoacylglycerol biosynthetic process
Knockout
CRISPR knockout of genes such as PLA2G15, PLD3, or PLD4 is used to determine their necessity for monoacylglycerol biosynthesis. For example, PLA2G15 knockout cells show accumulation of BMP and reduced monoacylglycerol. These models are valuable for linking genes to lipid phenotypes.
Point Mutation
Point mutations can mimic disease-associated variants, such as LRRK2 G2019S, to study their impact on monoacylglycerol metabolism. CRISPR-mediated knock-in of such mutations allows precise modeling of Parkinson's disease.
Knock-in
Knock-in of tagged or reporter genes (e.g., GFP-PLA2G15) enables visualization and tracking of enzyme localization and dynamics. This approach helps define where monoacylglycerol is produced within cells.
Overexpression
Overexpression of PLD3 or PLD4 can rescue BMP synthesis and increase monoacylglycerol production, confirming their roles. Overexpression models are useful for gain-of-function studies and for testing therapeutic hypotheses.
How EDITGENE Supports monoacylglycerol biosynthetic process Research
Researchers studying monoacylglycerol biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, lysosomal function, or disease. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for monoacylglycerol biosynthetic process research.
Frequently Asked Questions About monoacylglycerol biosynthetic process
What is monoacylglycerol biosynthetic process?
It is the set of biochemical reactions that produce monoacylglycerol, a glycerol ester with one fatty acid, as defined by GO:0006640.
What genes are involved in monoacylglycerol biosynthetic process?
Key genes include PLA2G15, PLD3, PLD4, LRRK2, and MOGAT family members.
How is monoacylglycerol synthesized in lysosomes?
Enzymes like PLA2G15 hydrolyze BMP to release monoacylglycerol within lysosomes.
What is the role of monoacylglycerol in disease?
It is linked to neurodegenerative diseases, lysosomal storage disorders, and metabolic conditions.
Which diseases are associated with monoacylglycerol metabolism?
Parkinson's disease, Niemann-Pick type C, and lysosomal diseases.
What methods are used to study monoacylglycerol biosynthesis?
Lipidomics, CRISPR screens, enzymatic assays, and imaging.
Can CRISPR be used to study monoacylglycerol biosynthesis?
Yes, knockout, knock-in, and overexpression models are widely used.
What is the link between LRRK2 and monoacylglycerol?
LRRK2 kinase activity regulates lysosomal lipids including BMP and monoacylglycerol.
How does cold exposure affect monoacylglycerol?
Cold exposure induces hepatic lipid remodeling and regulates BMP lipids via PLA2G15.
What are the therapeutic implications of targeting this pathway?
Targeting enzymes like PLA2G15 or PLD3/4 may ameliorate lysosomal disease.
Conclusion
The monoacylglycerol biosynthetic process (GO:0006640) is a critical metabolic pathway that produces monoacylglycerol, a lipid intermediate with essential roles in lysosomal function, membrane remodeling, and disease. Research has identified key enzymes such as PLA2G15, PLD3, and PLD4, and linked the pathway to Parkinson's disease, lysosomal storage disorders, and metabolic conditions. Continued investigation using CRISPR models and lipidomics will further elucidate its regulation and therapeutic potential.
References
- 1. Medoh UN et al.. 2024. The Bis(monoacylglycero)-phosphate Hypothesis: From Lysosomal Function to Therapeutic Avenues.. Annu Rev Biochem 93(1):447-469 PMID: 38603559
- 2. Maloney MT et al.. 2025. LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.. Mol Neurodegener 20(1):89 PMID: 40770658
- 3. Nyame K et al.. 2025. PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease.. Nature 642(8067):474-483 PMID: 40335701
- 4. Singh S et al.. 2024. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes.. Cell 187(24):6820-6834.e24 PMID: 39423811
- 5. Bulfon D et al.. 2024. Functionally overlapping intra- and extralysosomal pathways promote bis(monoacylglycero)phosphate synthesis in mammalian cells.. Nat Commun 15(1):9937 PMID: 39548099
- 6. Wei J et al.. 2023. Lipids as Emerging Biomarkers in Neurodegenerative Diseases.. Int J Mol Sci 25(1) PMID: 38203300
- 7. Davidson JW et al.. 2025. Hepatic lipid remodeling in cold exposure uncovers direct regulation of bis(monoacylglycero)phosphate lipids by phospholipase A2 group XV.. Cell Metab 37(6):1413-1425.e6 PMID: 40373767
- 8. Deng S et al.. 2024. Molecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiency.. J Biol Chem 300(11):107889 PMID: 39395801
